HERTHENA-Lung01: A Phase II Study of Patritumab Deruxtecan (HER3-DXd) in Previously Treated Metastatic <i>EGFR</i> -mutated NSCLC
この論文をさがす
説明
Antibody–drug conjugate; Non-small-cell lung cancer; Patritumab deruxtecan Conjugat anticossos-fàrmac; Càncer de pulmó de cèl·lules no petites; Patritumab deruxtecan Conjugado anticuerpo-fármaco; Cáncer de pulmón de células no pequeñas; Patritumab deruxtecan Limited treatment options exist for EGFR-mutated NSCLC that has progressed after EGFR TKI and platinum-based chemotherapy. HER3 is highly expressed in EGFR-mutated NSCLC, and its expression is associated with poor prognosis in some patients. Patritumab deruxtecan (HER3-DXd) is an investigational, potential first-in-class, HER3-directed antibody–drug conjugate consisting of a HER3 antibody attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. In an ongoing phase I study, HER3-DXd demonstrated promising antitumor activity and a tolerable safety profile in patients with EGFR-mutated NSCLC, with or without identified EGFR TKI resistance mechanisms, providing proof of concept of HER3-DXd. HERTHENA-Lung01 is a global, registrational, phase II trial further evaluating HER3-DXd in previously treated advanced EGFR-mutated NSCLC.
収録刊行物
-
- Future Oncology
-
Future Oncology 19 1319-1329, 2023-05-22
Informa UK Limited
- Tweet
キーワード
- :Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms [DISEASES]
- Anomalies cromosòmiques
- :neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares [ENFERMEDADES]
- :Genetic Phenomena::Genetic Variation::Mutation [PHENOMENA AND PROCESSES]
- :Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores]
- :aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::globulinas séricas::inmunoglobulinas::anticuerpos::inmunoconjugados [COMPUESTOS QUÍMICOS Y DROGAS]
- :Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Serum Globulins::Immunoglobulins::Antibodies::Immunoconjugates [CHEMICALS AND DRUGS]
- Immunoglobulines - Ús terapèutic
- :Other subheadings::Other subheadings::/drug therapy [Other subheadings]
- Pulmons - Càncer - Tractament
- :fenómenos genéticos::variación genética::mutación [FENÓMENOS Y PROCESOS]
詳細情報 詳細情報について
-
- CRID
- 1870584741587715840
-
- ISSN
- 17448301
- 14796694
-
- データソース種別
-
- OpenAIRE